Name

Coenzyme Q10 End Products Industrialization Project of Yuxi National High-tech Industrial Development Zone

Organizer

Yuxi Jiankun Biotechnology Co., Ltd

Location

No.23 Chuangxin Road, Lot 3, the southern area of Yuxi National High-tech Industrial Development Zone

State

Expansion project

Introduction

Yuxi Jiankun Biotechnology Co., Ltd. has devoted itself in the comprehensive development and use of tobacco wastes for many years. Now, it is capable of producing 15-ton coenzyme Q10 annually. In order to extend the industrial chain and promote the additional value of the products, the company intends to set up by the way of cooperation several production lines that can annually produce 20 million bottles of coenzyme Q10 capsules, 10 million tubes of coenzyme Q10 toothpaste, 5 tons of reduced coenzyme Q10, and 6 million bottles of water-soluble coenzyme Q10 granule series annually, realizing the industrialization of coenzyme Q10 end products. With RMB500 million-investment in total, the project is planned to be constructed in a year without acquiring any new building lot.

Implementation Principle

The project is consistent with the national and provincial policies that encourage and strengthen the development of biological medicines.

Construction Condition

The project construction site lies at the southern area of Yuxi National High-tech Industrial Development Zone. The phase-I project has already been in production and been capable of producing 15-ton coenzyme Q10 annually. The construction requirement of the expansion project has been thus satisfied.

Supply of Main and Supplementary Materials and Availability of Labor Resources

The principal raw materials of the coenzyme Q10 products are tobacco wastes. And Yuxi is among China’s largest flue-cured tobacco and cigarette producing areas. The principal raw materials of the project are available, and other auxiliary materials can be purchased directly on the market. The factory will limit the number of staff to 120 and these employees can be recruited from where the project is located.

First-Phase Preparations and Progress

The phase-I production workshop of the company has been completed, and manufacturing 98%-purity nicotine, 97%-high-purity solanesol, coenzyme Q10 products, and the like. At present, it is among the largest domestic production enterprises of coenzyme Q10 drug substances. The four sub-items of the end products, with independent intellectual property right, have passed the pilot plant test and qualified for industrialization. Now, the project has completed its feasibility study on expansion.

Environmental Impact

By virtue of advanced and reliable production technology, the project has greatly reduced the three-waste emissions and well treated the wastewater to meet the discharge standard, in case of polluting the surroundings of the factory site.

Investment Estimation & Fund Raising

The total investment of the project is RMB500 million. The project is proposed to be invested and constructed by the way of cooperation.

Preliminary Economic Benefit Analysis

The industrialization of four end products, namely coenzyme Q10 capsules, water-soluble coenzyme Q10 granule series, coenzyme Q10 toothpaste, reduced coenzyme Q10, is expected to generate RMB4.35 billion-sales revenue and RMB1.8 billion-profit.

Ways of Cooperation

Financing, contribution, holding, or buyout

Contact Info

Contact Unit: Yuxi Jiankun Biotechnology Co., Ltd.，Yuxi Municipality, Yunnan Province, P. R. China

Contact Person: Chen Linxian

Contact Tel.: 86-13908895200

Email: yxgxq@126.com